From the Guidelines
Subcutaneous NAD injections should not be administered based on the provided evidence, as it does not support the use of NAD injections for any medical condition. The provided evidence 1 discusses the guidelines for the management of psoriasis and psoriatic arthritis with biologics, specifically etanercept, and does not mention NAD injections. However, based on general medical knowledge, if NAD injections were to be considered, the frequency of administration would likely depend on various factors, including the individual's health goals and the practitioner's recommendations. Some possible regimens may involve:
- Starting with twice-weekly injections for the first month, then reducing to once weekly for maintenance
- Administering injections 1-3 times per week, with dosages ranging from 100-500mg per injection
- Rotating injection sites between the abdomen, thigh, or back of the arm to prevent tissue irritation
- Giving each injection slowly over 1-2 minutes to minimize discomfort It is essential to note that NAD injections are not supported by the provided evidence 1, and their use should be approached with caution, considering potential side effects such as flushing, nausea, or discomfort at the injection site. Always consult with a healthcare provider before beginning any new therapy, as individual health conditions may affect appropriate dosing and frequency.
From the Research
Frequency of Administering Subcutaneous NAD Injections
There are no research papers to assist in answering this question as the provided studies do not mention the administration of subcutaneous NAD (Nicotinamide Adenine Dinucleotide) injections. The studies focus on the administration of low molecular weight heparins, such as nadroparin and enoxaparin, for the prevention and treatment of thromboembolic disorders.
Administration Frequencies of Low Molecular Weight Heparins
- Nadroparin can be administered subcutaneously once daily, as seen in the study by 2, where patients received 60 aXa IU/kg once daily for 10 days.
- Enoxaparin can be administered subcutaneously twice daily, as seen in the study by 3, where patients received 1.0 mg/kg twice daily for a maximum of 48 hours.
- Nadroparin can also be administered subcutaneously twice daily, as seen in the study by 4, where patients received subcutaneous injections every 8 hours for a maximum of 48 hours.
- A once daily regimen of nadroparin (20,500 AXa IU/ml) can be as effective and safe as a twice daily regimen (10,250 AXa IU/ml) for the treatment of deep vein thrombosis, as shown in the study by 5.